You are here

Management of toxicities in special cases

Presentation by Dr. Benjamin Besse at the TAO Congress on 19/20 November 2015

TAO15 - BENJAMIN BESSE- New therapies and toxicities in cancer - Complexe cases-HD

Dr. Benjamin Besse is Head of the Thoracic Unit at the cancer-research institute and oncology health centre Institut Gustave Roussy. He provides an overview of disease segmentation based on oncogenic events, non-small-cell lung carcinoma (NSCLC) heterogeneity and EGFR mutations in lung cancer. After reviewing survival figures from several clinical trials, he presents clinical cases from his institute. Various therapeutic substances were used, for example bevacizumab, cisplatin, crizotinib, erlotinib, gemcitabine, paclitaxel, pemetrexed, vemurafenib, etc. Dr. Besse discusses the toxicities which occurred in these cases, such as rash, dry skin, alopecia, dyspnea, cough and hepatotoxicity, as well as the supportive care which they required. With new therapies available, many patients receive long-term treatment which leads to chronic toxicities; in view of the clinical case in which the patient has been receiving the epidermal growth factor receptor (EGFR) inhibitor erlotinib for 8.5 years, Dr. Besse discusses the question: When to stop?

The presentation is followed by comments from Dr. Richard Gralla (A. Einstein School of Medicine, New York, USA).


Dr. Benjamin Besse, Institut Gustave Roussy, Villejuif, France


Search this site

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

NEW! Free access to the digital version of a new publication in Cancer Supportive Care


Cancer cachexia: mechanisms and progress in treatment

Authors: Egidio Del Fabbro, Kenneth Fearon, Florian Strasser

This book was supported by an educational grant from Helsinn Healthcare SA.

Featured videos

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo

Share